Pulmonary Arterial Hypertension
📧 Sign up to get email alerts when something new happens for Pulmonary Arterial Hypertension.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-08-22Clinical Trial Update: Digital Assessment of Real-World Walking Activity in Pulmonary Hypertension: A Prospective Multicenter Trial
A prospective multicenter clinical trial evaluating digital, real-world walking activity measurements in patients with pulmonary hypertensio…
-
FDA approval · 2025-08-20FDA Approved: AMBRISENTAN — Supplemental Application (Zydus Lifesciences Limited)
FDA approved a supplemental application for AMBRISENTAN (ambrisentan) from Zydus Lifesciences Limited.
-
FDA approval · 2025-08-20FDA Approved: MACITENTAN — Original Application (Sandoz Inc)
FDA approved a generic macitentan from Sandoz Inc through an original application for the treatment of pulmonary arterial hypertension.
-
CLINICAL_TRIALS research · 2025-08-20Clinical Trial Update: Understanding the Effects of Pulmonary Arterial Hypertension on Lean Muscle Mass
A University of Pennsylvania-led study investigates how pulmonary arterial hypertension affects lean muscle mass.
-
CLINICAL_TRIALS research · 2025-08-15Clinical Trial Update: A Study to Observe the Safety, Tolerability, and Efficacy of Remodulin
This entry describes a planned clinical trial to evaluate the safety, tolerability, and efficacy of Remodulin (treprostinil) in people with …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-08-14Clinical Trial Update: The MObile Health InterVEntion in Pulmonary Arterial Hypertension (MOVE PAH) Study [NA]
The MOVE PAH clinical trial, evaluating a mobile health intervention for pulmonary arterial hypertension, is currently recruiting at Vanderb…
-
CLINICAL_TRIALS trial_result · 2025-08-05Clinical Trial Update: Single Ascending Dose Study for Evaluation of Safety, Tolerability and Pharmacokinetics of L606 [Phase 1]
Phase 1 single ascending dose study evaluating safety, tolerability, and pharmacokinetics of L606 has completed. The study targeted pulmonar…
-
CLINICAL_TRIALS research · 2025-08-01Clinical Trial Update: Pulmonary Hypertension Biorepository and Registry
A pulmonary hypertension biorepository and registry sponsored by the University of Kansas Medical Center is actively recruiting (NCT04808596…
-
CLINICAL_TRIALS trial_result · 2025-08-01Clinical Trial Update: Novel Index (PIMR) in PAH
A completed clinical study evaluating the Novel Index (PIMR) in pulmonary arterial hypertension, sponsored by the University of California, …
-
EMA approval · 2025-07-31EMA Authorised: Trepulmix (treprostinil sodium) — SciPharm Sàrl
The European Medicines Agency authorised Trepulmix (treprostinil sodium) for the treatment of pulmonary arterial hypertension and it carries…
-
FDA approval · 2025-07-30FDA Approved: TRACLEER — Supplemental Application (Actelion Pharmaceuticals US, Inc.)
The FDA approved a supplemental application for TRACLEER (bosentan) from Actelion Pharmaceuticals US, updating the product’s label.
-
FDA approval · 2025-07-30FDA Approved: TRACLEER — Supplemental Application (Actelion Pharmaceuticals US, Inc.)
The FDA approved a supplemental application for Tracleer (bosentan) by Actelion Pharmaceuticals US, Inc. The action affects its use in pulmo…
-
CLINICAL_TRIALS research · 2025-07-29Clinical Trial Update: Comparison of Sequential to Initial Combination Therapy in PAH [NA]
This clinical trial is investigating sequential versus initial combination therapy in pulmonary arterial hypertension and is currently recru…
-
FDA approval · 2025-07-25FDA Approved: AMBRISENTAN — Supplemental Application (Mylan Pharmaceuticals Inc.)
FDA approved a supplemental application for ambrisentan from Mylan Pharmaceuticals Inc., signaling regulatory approval related to this gener…
-
CLINICAL_TRIALS trial_result · 2025-07-25Clinical Trial Update: Quality of Life Assessed With the PAH SYMPACT Questionnaire
The clinical trial update summarizes quality-of-life findings in pulmonary hypertension using the PAH SYMPACT questionnaire.
-
CLINICAL_TRIALS research · 2025-07-24Clinical Trial Update: Long-term Survival and Influencing Factors of Patients With Pulmonary Arterial Hypertension and Diabetes
This clinical trial update discusses long-term survival and factors influencing outcomes in patients with pulmonary arterial hypertension an…
-
FDA approval · 2025-07-18FDA Approved: AMBRISENTAN — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for Ambrisentan by Aurobindo Pharma Limited, authorizing a generic version of the drug.
-
CLINICAL_TRIALS trial_result · 2025-07-10Clinical Trial Update: Melatonin for Pulmonary Hypertension in Full Term Neonates [Phase 3]
Phase 3 trial evaluating melatonin for pulmonary hypertension in full-term neonates has completed.
-
FDA approval · 2025-06-30FDA Approved: SILDENAFIL — Supplemental Application (Macleods Pharmaceuticals Limited)
FDA approved a supplemental application for sildenafil (generic) from Macleods Pharmaceuticals Limited, authorizing the marketing of a gener…
-
CLINICAL_TRIALS research · 2025-06-26Clinical Trial Update: Real-World Study of PADN for the Treatment of PAH
A real-world study evaluating pulmonary artery denervation (PADN) for treating pulmonary arterial hypertension is currently recruiting.
-
CLINICAL_TRIALS research · 2025-06-26Clinical Trial Update: National Registry and Cohort Study of Pulmonary Vascular Disease
This entry reports a national registry and cohort study on pulmonary vascular disease focusing on Pulmonary Arterial Hypertension, currently…
-
CLINICAL_TRIALS trial_result · 2025-06-25Clinical Trial Update: A Study of Pulmonary Arterial Hypertension Participants Treated With Macitentan or Selexipag
A completed clinical trial update describing a study in pulmonary arterial hypertension comparing macitentan versus selexipag.
-
CLINICAL_TRIALS withdrawal · 2025-06-22Clinical Trial Update: Correlation of LONGterm Wrist ACTigraphy Recorded Physical Performance & 6-minute Walk Distance in Patients With Pulmonary Arterial Hypertension
This clinical trial update notes the withdrawal of a study assessing the relationship between long-term wrist actigraphy-based physical perf…
-
CLINICAL_TRIALS withdrawal · 2025-06-13Clinical Trial Update: A Phase 2 Study of IkT-001Pro in Pulmonary Arterial Hypertension (PAH) [Phase 2]
A Phase 2 study of IkT-001Pro for pulmonary arterial hypertension has been withdrawn.
-
CLINICAL_TRIALS research · 2025-06-10Clinical Trial Update: imprOving Adherence to Pulmonary artErial hyperteNsion Treatment With teLemedicIne and patieNt guidaNce [NA]
The study aims to improve adherence to pulmonary arterial hypertension treatment by using telemedicine and patient guidance. It is currently…